Authorities are considering whether to approve a new drug to treat Alzheimer’s disease after a participant reportedly died while taking part in an experimental clinical trial.
A new report in the New England Journal of Medicine said the passing of a 65-year-old in the early stages of the condition may have been related to infusions of lecanemab given four days earlier.
The patient was rushed to the hospital in Chicago within 30 minutes after displaying signs of a stroke, but later died after a common treatment used to break up blood clots named t-PA failed.
